Anti-CD62L Antibody (DREG-200)

Anti-CD62L Antibody (DREG-200) (15 μg/10⁶ neutrophils; 0.5-1 h) blocks the enhanced IL-8-induced chemotaxis of isolated human peripheral blood neutrophils by L-NAME (HY-18729A), and inhibits the ability of L-NAME-induced human neutrophil-derived microparticles to enhance IL-8-induced chemotaxis of isolated human peripheral blood neutrophils^[1].
Anti-CD62L Antibody (DREG-200) (at saturated concentration; incubated at 4°C for 30 min) detects the expression of L-selectin on human neutrophil-derived microparticles^[1].
Anti-CD62L Antibody (DREG-200) (40 μg/mL; 30 min) specifically binds to unstimulated feline neutrophils^[2].
Anti-CD62L Antibody (DREG-200) (10-40 μg/mL; 5 min PMN preincubation, 20 min incubation at 4°C) inhibits the adhesion of unstimulated feline polymorphonuclear leukocytes (PMN) to ischemic/reperfused feline coronary vascular endothelium in a concentration-dependent manner, while exerting no effect on their adhesion to normal endothelium^[2].
Anti-CD62L Antibody (DREG-200) blocks L-selectin-mediated rolling of primary human blood lymphocytes on immobilized PSGL-1-Fc under flow conditions^[3].
Anti-CD62L Antibody (DREG-200) blocks L-selectin-mediated rolling of Jurkat cells on immobilized PSGL-1-Fc, E-selectin-Fc, PNAd and sLex-PAA under flow conditions^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.